Status: Recruiting
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).
Participants needed: 40
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Anita SarafUpdated: Oct 6, 2025Locations: 3
Eligibility criteria
Diagnoses of Congenital Heart Disease [+5]
Diagnosed with Diabetes [+13]